pharma · COPD (Chronic Obstructive Pulmonary Disease) · Uncontrolled Asthma
Chiesi Farmaceutici S.p.A
Chiesi Farmaceutici S.p.A.
Chiesi Farmaceutici S.p.A is a pharma organization headquartered in Parma, IT. Primary therapeutic focus areas include COPD (Chronic Obstructive Pulmonary Disease), Uncontrolled Asthma. NovaPharmaNews links 2 clinical pr
Parma, IT HQ
6,080 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Parma, IT
- Employees
- 6,080
- Programs
- 2
- Drugs
- 3
- Patents
- 0
CHF 5993 100/6/12.5 µg
Phase 3 · small molecule · COPD (Chronic Obstructive Pulmonary Disease)
CHF 5993 100/6/12.5 µg for COPD (Chronic Obstructive Pulmonary Disease) is a Phase 3 program (small_molecule) at Chiesi Farmaceutici S.p.A. with 1 ClinicalTrials.gov record(s).
Internal code CCD-5993AA1-14
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- COPD (Chronic Obstructive Pulmonary Disease)
- Status
- completed
- Trials
- 1